A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
May 26, 2022 at 14:20 PM EDT
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
